

Luigi Aloj

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5962001/publications.pdf>

Version: 2024-02-01

76
papers

2,031
citations

236925

25
h-index

265206

42
g-index

76
all docs

76
docs citations

76
times ranked

2751
citing authors

#	ARTICLE	IF	CITATIONS
1	18F-FDG PET is an early predictor of pathologic tumor response to preoperative radiochemotherapy in locally advanced rectal cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1241-8.	5.0	157
2	Supramolecular aggregates containing lipophilic Gd(III) complexes as contrast agents in MRI. <i>Coordination Chemistry Reviews</i> , 2009, 253, 2193-2213.	18.8	124
3	Comparative biodistribution of 12 111In-labelled gastrin/CCK2 receptor-targeting peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1410-1416.	6.4	88
4	Preliminary results for positron emission mammography: real-time functional breast imaging in a conventional mammography gantry. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996, 23, 804-806.	2.1	87
5	The Role of 18F-FDG-PET in the Local/Regional Evaluation of Women with Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2002, 75, 135-146.	2.5	78
6	In vitro and in vivo evaluation of 111In-DTPAGlu-G-CCK8 for cholecystokinin-B receptor imaging. <i>Journal of Nuclear Medicine</i> , 2004, 45, 485-94.	5.0	70
7	Cellular Release of [18F]2-Fluoro-2-deoxyglucose as a Function of the Glucose-6-phosphatase Enzyme System. <i>Journal of Biological Chemistry</i> , 2000, 275, 18489-18494.	3.4	68
8	Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2/gastrin receptor binding peptides: a collaborative project under COST Action BM0607. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1417-1425.	6.4	63
9	Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. <i>Journal of Neurosurgery</i> , 1995, 83, 657-664.	1.6	62
10	Early FDG PET response assessment of preoperative radiochemotherapy in locally advanced rectal cancer: correlation with long-term outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 39, 1848-1857.	6.4	53
11	Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs. <i>International Journal of Nanomedicine</i> , 2014, 9, 1537.	6.7	53
12	Early PET/CT Scan Is More Effective Than RECIST in Predicting Outcome of Patients with Liver Metastases from Colorectal Cancer Treated with Preoperative Chemotherapy Plus Bevacizumab. <i>Journal of Nuclear Medicine</i> , 2013, 54, 2062-2069.	5.0	51
13	Acute administration of antipsychotics modulates Homer striatal gene expression differentially. <i>Molecular Brain Research</i> , 2002, 98, 124-129.	2.3	47
14	Role of 68Ga-DOTATATE PET/CT in patients with multiple endocrine neoplasia type 1 (MEN1). <i>Endocrine</i> , 2016, 52, 488-494.	2.3	47
15	Standardized Index of Shape (DCE-MRI) and Standardized Uptake Value (PET/CT): Two quantitative approaches to discriminate chemo-radiotherapy locally advanced rectal cancer responders under a functional profile. <i>Oncotarget</i> , 2017, 8, 8143-8153.	1.8	46
16	Critical role of bevacizumab scheduling in combination with pre-surgical chemo-radiotherapy in MRI-defined high-risk locally advanced rectal cancer: results of the branch trial. <i>Oncotarget</i> , 2015, 6, 30394-30407.	1.8	44
17	Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 867-877.	6.4	40
18	Peptide-modified liposomes for selective targeting of bombesin receptors overexpressed by cancer cells: a potential theranostic agent. <i>International Journal of Nanomedicine</i> , 2012, 7, 2007.	6.7	37

#	ARTICLE	IF	CITATIONS
19	Phase 1/2 study of valproic acid and short-course radiotherapy plus capecitabine as preoperative treatment in low-moderate risk rectal cancer-V-shoRT-R3 (Valproic acid - short RadioTherapy - rectum) Tj ETQq1 1 0z784314 rgBT /Ove	2.8	14
20	Peptide modified nanocarriers for selective targeting of bombesin receptors. <i>Molecular BioSystems</i> , 2010, 6, 878.	2.9	35
21	Bombesin peptide antagonist for target-selective delivery of liposomal doxorubicin on cancer cells. <i>Journal of Drug Targeting</i> , 2013, 21, 240-249.	4.4	31
22	Inhibition of early ^{99m} Tc-MIBI uptake by Bcl-2 anti-apoptotic protein overexpression in untreated breast carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 879-887.	6.4	30
23	Use of neoadjuvant electrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 131.	4.4	30
24	Peptide-Containing Aggregates as Selective Nanocarriers for Therapeutics. <i>ChemMedChem</i> , 2008, 3, 594-602.	3.2	28
25	Influence of a novel, versatile bifunctional chelator on theranostic properties of a minigastrin analogue. <i>EJNMMI Research</i> , 2015, 5, 74.	2.5	28
26	Different Serum Enzyme Levels Are Required to Rescue the Various Systemic Features of the Mucopolysaccharidoses. <i>Human Gene Therapy</i> , 2010, 21, 555-569.	2.7	24
27	Evaluation of a CdTe semiconductor based compact gamma camera for sentinel lymph node imaging. <i>Medical Physics</i> , 2011, 38, 1547-1560.	3.0	24
28	Bcl-2 overexpression prevents ^{99m} Tc-MIBI uptake in breast cancer cell lines. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004, 31, 521-527.	6.4	23
29	Biophysical and biochemical characterization of a liposarcoma-derived recombinant MnSOD protein acting as an anticancer agent. <i>International Journal of Cancer</i> , 2008, 123, 2684-2695.	5.1	23
30	Noninvasive Repetitive Imaging of Somatostatin Receptor 2 Gene Transfer with Positron Emission Tomography. <i>Human Gene Therapy</i> , 2011, 22, 189-196.	2.7	23
31	Intravital Imaging of Adoptive T-Cell Morphology, Mobility and Trafficking Following Immune Checkpoint Inhibition in a Mouse Melanoma Model. <i>Frontiers in Immunology</i> , 2020, 11, 1514.	4.8	23
32	Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumors. <i>EJNMMI Research</i> , 2016, 6, 17.	2.5	22
33	Functional characterization of brain tumors: An overview of the potential clinical value. <i>Nuclear Medicine and Biology</i> , 1996, 23, 699-715.	0.6	21
34	Evaluation of Tumor Response after Short-Course Radiotherapy and Delayed Surgery for Rectal Cancer. <i>PLoS ONE</i> , 2016, 11, e0160732.	2.5	19
35	Comparison of an ¹⁸ F Labeled Derivative of Vasoactive Intestinal Peptide and 2-Deoxy-2-[¹⁸ F]Fluoro-D-Glucose in Nude Mice Bearing Breast Cancer Xenografts. <i>Molecular Imaging and Biology</i> , 2002, 4, 369-379.	2.6	18
36	Criteria for the Design and Biological Characterization of Radiolabeled Peptide-Based Pharmaceuticals. <i>BioDrugs</i> , 2004, 18, 279-295.	4.6	18

#	ARTICLE	IF	CITATIONS
37	A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization) Tj ETQq1 1 2017843141gBT /Ovel	10.7	4314
38	¹⁸ F-FDG PET/CT Is an Early Predictor of Pathologic Tumor Response and Survival After Preoperative Radiochemotherapy with Bevacizumab in High-Risk Locally Advanced Rectal Cancer. Journal of Nuclear Medicine, 2019, 60, 1560-1568.	5.0	18
39	Novel Approach to Imaging Active Takayasu Arteritis Using Somatostatin Receptor Positron Emission Tomography/Magnetic Resonance Imaging. Circulation: Cardiovascular Imaging, 2020, 13, e010389.	2.6	18
40	Polarized secretion of plasminogen activators by epithelial cell monolayers. Biochimica Et Biophysica Acta - Molecular Cell Research, 1992, 1175, 1-6.	4.1	17
41	Dynamic coupling of ^{99m} Tc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2002, 29, 809-814.	6.4	16
42	The [Tc(N)(PNP)] ²⁺ metal fragment labeled cholecystinin-8 (CCK8) peptide for CCK-2 receptors imaging:in vitro andin vivo studies. Journal of Peptide Science, 2007, 13, 211-219.	1.4	16
43	Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer. JAMA Network Open, 2021, 4, e2118475.	5.9	16
44	Pericoronary and periaortic adipose tissue density are associated with inflammatory disease activity in Takayasu arteritis and atherosclerosis. European Heart Journal Open, 2021, 1, oeab019.	2.3	15
45	Imaging and treatment of brain tumors through molecular targeting: Recent clinical advances. European Journal of Radiology, 2021, 142, 109842.	2.6	15
46	A Cyclic CCK8 Analogue Selective for the Cholecystinin Type A Receptor: Design, Synthesis, NMR Structure and Binding Measurements. ChemBioChem, 2003, 4, 1176-1187.	2.6	14
47	In vivo and in vitro characterization of CCK8 bearing a histidine-based chelator labeled with ^{99m} Tc-tricarboxyl. Biopolymers, 2008, 90, 707-712.	2.4	14
48	Gastrin and cholecystinin peptide-based radiopharmaceuticals: an <i>in vivo</i> and <i>in vitro</i> comparison. Journal of Peptide Science, 2011, 17, 405-412.	1.4	14
49	Multidisciplinary Approach to Rectal Cancer: Are we Ready for Selective Treatment Strategies?. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 852-860.	1.7	14
50	Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma. , 2021, 9, e003125.		13
51	Surgical Management of Sentinel Lymph Node Biopsy Outside Major Nodal Basin in Patients with Cutaneous Melanoma. Annals of Surgical Oncology, 2014, 21, 300-305.	1.5	12
52	Anthranilic Acid Based CCK1Receptor Antagonists and CCK-8 Have a Common Step in Their Receptor Desmodynamic Processes Journal of Medicinal Chemistry, 2006, 49, 2456-2462.	6.4	11
53	In Vivo Cell Tracking Using PET: Opportunities and Challenges for Clinical Translation in Oncology. Cancers, 2021, 13, 4042.	3.7	11
54	Conformationally Constrained CCK8 Analogues Obtained from a Rationally Designed Peptide Library as Ligands for Cholecystinin Type B Receptor. ChemMedChem, 2006, 1, 997-1006.	3.2	10

#	ARTICLE	IF	CITATIONS
55	Sequential PET/CT with [18F]-FDG Predicts Pathological Tumor Response to Preoperative Short Course Radiotherapy with Delayed Surgery in Patients with Locally Advanced Rectal Cancer Using Logistic Regression Analysis. PLoS ONE, 2017, 12, e0169462.	2.5	10
56	White matter lesion detection in multiple sclerosis: improved interobserver concordance with multispectral MRI display. Journal of Neurology, 1997, 244, 586-590.	3.6	9
57	3D printing 18F radioactive phantoms for PET imaging. EJNMMI Physics, 2021, 8, 38.	2.7	9
58	Detection limit of 89Zr-labeled T cells for cellular tracking: an in vitro imaging approach using clinical PET/CT and PET/MRI. EJNMMI Research, 2020, 10, 82.	2.5	9
59	The Glucocorticoid Analog Dexamethasone Alters the Expression and the Distribution of Dopamine Receptors and Enkephalin within Cortico- Subcortical Regions. Current Molecular Pharmacology, 2014, 6, 149-155.	1.5	8
60	A phase II study of dose-dense and dose-intense ABVD (ABVD _{DD}) without consolidation radiotherapy in patients with advanced Hodgkin lymphoma. British Journal of Haematology, 2014, 166, 118-129.	2.5	8
61	The expression of genes involved in glucose metabolism is affected by N-methyl-D-aspartate receptor antagonism: A putative link between metabolism and an animal model of psychosis. Journal of Neuroscience Research, 2012, 90, 1756-1767.	2.9	7
62	Synthesis and biological evaluation of cyclic and branched peptide analogues as ligands for cholecystokinin type 1 receptor. Bioorganic and Medicinal Chemistry, 2007, 15, 5845-5853.	3.0	6
63	The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy. Nuclear Medicine and Biology, 2021, 92, 53-64.	0.6	5
64	The role of [68Ga]Ga-DOTATATE PET/CT in wild-type KIT/PDGFRα gastrointestinal stromal tumours (GIST). EJNMMI Research, 2021, 11, 5.	2.5	4
65	An approach to a patient with primary hyperparathyroidism and a suspected ectopic parathyroid adenoma. Journal of Clinical Endocrinology and Metabolism, 2022, , .	3.6	4
66	Localization of TSH-secreting pituitary adenoma using 11C-methionine image subtraction. EJNMMI Research, 2022, 12, 26.	2.5	4
67	Effects of a human compact anti-ErbB2 antibody on prostate cancer. Oncology Reports, 2012, 28, 297-302.	2.6	3
68	A perspective on the current treatment strategies for locally advanced rectal cancer. International Journal of Biochemistry and Cell Biology, 2015, 65, 192-196.	2.8	3
69	Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases. World Journal of Nuclear Medicine, 2021, 20, 139.	0.5	3
70	Efficacy and safety of the third-generation chloroethylnitrosourea fotemustine for the treatment of chemorefractory T-cell lymphomas. European Journal of Haematology, 2011, 87, 547-553.	2.2	2
71	Evaluation of CCK2 receptor binding ligands: the inheritance of Thomas Behr. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 1407-1409.	6.4	2
72	Abstract LB-219: Neoadjuvant multidisciplinary phase II study (BRANCH) of an early bevacizumab schedule plus chemo-radiation therapy in rectal cancer: efficacy, safety, and biomarkers.. , 2012, , .		1

#	ARTICLE	IF	CITATIONS
73	Peptide-chelating agent conjugate for selective targeting of somatostatin receptor type 1: Synthesis and characterization. <i>Biopolymers</i> , 2004, 76, 527-534.	2.4	0
74	Role of Positron Emission Tomography/Computed Tomography. <i>Updates in Surgery Series</i> , 2016, , 39-48.	0.1	0
75	Early PET/CT scan compared with RECIST to predict long-term outcome of patients with liver metastases from colorectal cancer treated with preoperative chemotherapy plus bevacizumab.. <i>Journal of Clinical Oncology</i> , 2013, 31, 11008-11008.	1.6	0
76	Differential Adaptive Changes in Dopaminergic System by Acute vs. Subchronic Ketamine: Relevance for Psychosis Pathophysiology and Treatment. <i>Current Signal Transduction Therapy</i> , 2013, 8, 119-128.	0.5	0